2025-10-11 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data you provided, structured as requested:

## Teladoc Health Inc. (TDOC) Analysis

**Company Overview:** Teladoc Health Inc. is a telehealth company that provides virtual healthcare services.

### 1. Performance vs. S&P 500 (VOO)

**Key Figures:**

*   **TDOC Cumulative Return:** -61.03%
*   **VOO Cumulative Return:** 100.12%
*   **Absolute Divergence:** -156.9
*   **Relative Divergence:** 1.2
*   **Divergence Range:** min: -162.5, max: 312.6

**Analysis:**

TDOC has significantly underperformed the S&P 500 (VOO). The cumulative return difference is substantial (-156.9%).  The relative divergence of 1.2 suggests that TDOC is positioned towards the lower end of its historical performance range relative to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR     | MDD      | Alpha    | Beta    | Cap(B) |
|------------|----------|----------|----------|---------|--------|
| 2015-2017  | 77.0%    | 70.4%    | 51.0%    | -0.1    | 6.2    |
| 2016-2018  | 101.0%   | 69.4%    | 86.0%    | -0.1    | 8.8    |
| 2017-2019  | 141.0%   | 73.8%    | 118.0%   | 0.3     | 14.8   |
| 2018-2020  | 105.0%   | 80.9%    | 81.0%    | 0.3     | 35.3   |
| 2019-2021  | -78.0%   | 80.9%    | -125.0%  | 0.3     | 16.2   |
| 2020-2022  | -252.0%  | 85.9%    | -251.0%  | -0.9    | 4.2    |
| 2021-2023  | -315.0%  | 85.9%    | -316.0%  | -1.8    | 3.8    |
| 2022-2024  | -93.0%   | 85.9%    | -113.0%  | -1.9    | 1.6    |
| 2023-2025  | -32.0%   | 81.6%    | -96.0%   | -0.8    | 1.4    |

**Analysis:**

*   **CAGR:** The CAGR (Compound Annual Growth Rate) shows a drastic decline in recent years, turning negative.
*   **MDD:** The Maximum Drawdown (MDD) remains high, indicating significant risk and volatility.
*   **Alpha:** Alpha has been predominantly negative in recent periods, indicating underperformance relative to its benchmark.
*   **Beta:** Beta values are mostly negative, suggesting an inverse correlation or lower correlation with the market.  The magnitude of the negative beta has increased recently, suggesting TDOC may be acting as a hedge in recent years, moving against the overall market trend.
*   **Cap(B):** Market Cap has decreased from 35.3B to 1.4B over the years.

### 2. Recent Price Action

**Key Figures:**

*   **Current Price:** 8.1
*   **Last Market Data:** {'price': 8.085, 'previousClose': 8.85, 'change': -8.64}
*   **5-day Moving Average:** 8.628
*   **20-day Moving Average:** 8.172
*   **60-day Moving Average:** 7.7806

**Analysis:**

The recent price is below the 5-day and 20-day moving averages, but above the 60-day moving average. This suggests potential short-term weakness but possible longer-term support. The `change` value indicates a recent significant drop.

### 3. Market Risk Indicators & Expected Return

**Key Figures:**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 51.44
*   **PPO:** 0.31
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (110 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** 1.0 (+) (Short-term Increase)
*   **Expected Return (%):** -7873.7

**Analysis:**

*   **MRI:** The MRI suggests a medium level of investment risk.
*   **RSI:** The RSI is near neutral, not indicating overbought or oversold conditions.
*   **PPO:** PPO suggests price trending is weak, but slightly trending upwards.
*   **Hybrid Signal:** The hybrid signal recommends buying, deeming it safe based on the MRI.
*   **Recent Divergence Change:** The positive change in relative divergence suggests some short-term upward momentum, but it's important to remember this is relative to TDOC's own past performance vs. the S&P 500.
*   **Expected Return:** The extremely negative expected return is highly concerning and implies significant challenges for TDOC to outperform the S&P 500 in the long term. This may be an anomaly or a reflection of deeply negative sentiment and historical performance.

### 4. Recent News & Significant Events

*   **Negative Headlines:** Multiple headlines highlight negative stock performance ("Trade Down") alongside peers.
*   **Positive Headlines:** Some articles suggest potential for the medical service industry and highlight successful EHR rollout.
*   **Mixed Headlines:** Some articles discuss Teladoc's performance relative to peers in the online marketplace sector, suggesting a need for comparative analysis.

**Impact:** The news sentiment appears mixed, with some positive developments offset by concerns about stock performance.

### 4-2. Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (Hold)
*   **Target Price:** 9.18 (Average), 12.00 (High), 7.00 (Low)

**Analysis:**

Analysts have a consensus "Hold" rating, with an average target price slightly above the current price. This suggests limited upside potential, but also limited downside risk according to analyst estimates. The lack of recent rating changes suggests a stable outlook.

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 매출        |
|--------------|--------|-------------|
| 2025-07-30   | -0.19  | 0.63 B$     |
| 2025-05-01   | -0.53  | 0.63 B$     |
| 2024-10-31   | -0.19  | 0.64 B$     |
| 2024-08-01   | -4.92  | 0.64 B$     |
| 2025-07-30   | -4.92  | 0.64 B$     |

**Analysis:**

*   **EPS:**  Earnings per share (EPS) has been consistently negative. There was a big loss on 2024-08-01 and 2025-07-30 (-4.92).
*   **Revenue:** Revenue has remained relatively stable around $0.63-0.64 billion.

This indicates that while the company is generating revenue, it is not profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $0.63B     | 69.85%        |
| 2025-03-31 | $0.63B     | 68.73%        |
| 2024-12-31 | $0.64B     | 70.50%        |
| 2024-09-30 | $0.64B     | 71.94%        |
| 2024-06-30 | $0.64B     | 70.73%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-06-30 | $1.42B     | -2.30%    |
| 2025-03-31 | $1.43B     | -6.52%    |
| 2024-12-31 | $1.49B     | -3.25%    |
| 2024-09-30 | $1.51B     | -2.21%    |
| 2024-06-30 | $1.50B     | -55.77%   |

**Analysis:**

*   **Revenue and Profit Margin:**  While revenue is relatively stable, the profit margin is decent, suggesting the company can generate income from its sales.
*   **Equity:** Equity is decreasing slowly.
*   **ROE:**  Return on Equity (ROE) is negative, reflecting the company's inability to generate profit from shareholder equity. The large negative ROE in Q2 2024 is particularly concerning.

### 7. Overall Assessment

**Summary:**

Teladoc Health (TDOC) faces significant challenges. It has dramatically underperformed the S&P 500, experiences high volatility, and struggles with profitability. Recent earnings and financial data reveal consistent losses and a concerning decline in equity. While the MRI suggests a medium level of investment risk, the extremely negative expected return and negative analyst consensus warrant caution.

**Key Concerns:**

*   **Underperformance:**  Significant underperformance relative to the market.
*   **Profitability:**  Consistent losses and negative ROE.
*   **High Volatility:** Indicated by large MDD and price swings.
*   **Negative Sentiment:** Reflected in news headlines and negative expected return.

**Potential Positives:**

*   **Revenue Generation:** Consistent revenue indicates a demand for their services.
*   **Analyst Hold Rating:**  Suggests a possibility of stabilization around current levels.
*   **Recent Divergence:** Slight uptrend is seen in recent data.

**Conclusion:**

Based on the provided data, investing in TDOC appears risky. A turnaround would require significant improvements in profitability, a shift in market sentiment, and a demonstration of sustainable growth. Investors should proceed with extreme caution and conduct thorough due diligence.
